Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.– What kind of treatment is Donanemab?
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in researc
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a type of drug called a monoclonal antibody, which is given by infusion (through a drip in the arm).
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the “relatively small benefit” it provides does not outweigh its cost.1 The draft guidelines,
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of its cost-effectiveness.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
New Alzheimer’s drugs should be available on NHS, says patient’s wife
New Alzheimer’s drugs should be available on NHS, says patient’s wife - New disease-modifying drugs work best when they are given to patients in the early stages of the disease.
New Alzheimer’s drug rejected for widespread NHS use in England
Donanemab, a pioneering new drug that can treat Alzheimer's, has been rejected by the health spending watchdog.
News Medical on MSN10h
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Alzheimer's Society3d
Alzheimer's Society responds to MHRA and NICE announcements on donanemab
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...
Manchester Evening News on MSN3d
New Alzheimer’s drug donanemab rejected for widespread use in NHS
Despite the UK’s medicines regulator hinting at a possible licence for donanemab's use in the country, it is the second ...
Arkansas group suggests ways to improve care for Alzheimer’s, dementia patients
Expanding public education, increasing access and quality of care, supporting family caregivers and increasing training for ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...